In a significant development for Indoco Remedies , the Kare Family Private Trust has completed a substantial share acquisition through off-market transfers dated December 26, 2025. The transaction, executed as part of family succession planning, involved the transfer of shares from Aruna Suresh Kare to the trust without any monetary consideration.

Transaction Details

The regulatory disclosure filed on December 30, 2025, reveals the completion of a major intra-promoter share transfer. The Kare Family Private Trust acquired 55.34 lakh shares representing 6.00% of Indoco Remedies' total share capital from Aruna Suresh Kare through off-market transfer.

Current Shareholding Pattern

Following the completion of this transaction, the Kare Family Private Trust now holds a consolidated position in Indoco Remedies. The trust's shareholding structure demonstrates a strategic consolidation of family assets.

Family Trust Structure

The Kare Family Private Trust was established on November 22, 2024, specifically for smooth succession planning and streamlining family assets and businesses. The trust structure includes Suresh Govind Kare and Aruna Suresh Kare as settlors, while Aditi Milind Panandikar and Madhura Suresh Kare serve as beneficiaries. All parties involved are existing promoters of Indoco Remedies.

Regulatory Compliance

The transaction has been executed in full compliance with SEBI regulations, with appropriate disclosures made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company's equity share capital remains unchanged at ₹18.45 crores, divided into 9.22 crore equity shares of ₹2 each.

Market Impact

This intra-promoter transfer represents a private family arrangement and does not alter the overall promoter shareholding percentage in Indoco Remedies. The transaction strengthens the family's succession planning framework while maintaining the existing control structure of the pharmaceutical company.

Indoco Remedies has achieved a significant regulatory milestone with the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) manufacturing facility in Patalganga. The company announced this development through a regulatory filing, following a successful USFDA inspection.

Regulatory Milestone Details

The EIR from USFDA represents successful completion of the regulatory inspection process for the Patalganga facility. This approval confirms that the manufacturing plant meets the stringent quality standards and regulatory requirements mandated by the US health authority.

Strategic Significance

The USFDA EIR approval enhances Indoco Remedies' manufacturing credentials and regulatory standing in the international pharmaceutical market. This certification enables the company to supply APIs manufactured at the Patalganga facility to customers in the United States, one of the world's largest and most lucrative pharmaceutical markets.

The approval demonstrates the company's commitment to maintaining high-quality manufacturing standards and regulatory compliance across its operations. For pharmaceutical companies, USFDA approvals are crucial for accessing the US market and establishing credibility with international customers.

Company Profile

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company operates with a turnover of USD 180.00 million and employs over 6,000 people, including more than 400 skilled scientists and field staff.

This regulatory achievement positions Indoco Remedies favorably for potential business expansion in the US pharmaceutical market and strengthens the company's competitive position in the global API manufacturing sector.